Published in Thromb Haemost on March 02, 1992
Interactions of anti-DNA antibodies with Z-DNA. Clin Exp Immunol (1993) 0.77
A raised beta 2-glycoprotein I level does not prolong the DRVVT. Thromb Haemost (1992) 0.75
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2009) 4.95
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost (2005) 3.47
Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost (2007) 2.86
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med (1997) 2.41
No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol (1998) 2.18
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 2.16
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol (2000) 2.09
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia (2007) 2.09
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood (1990) 2.04
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.96
Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost (1993) 1.65
Disseminated human herpesvirus 6 infection in AIDS. Lancet (1993) 1.64
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia (2010) 1.63
Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat (2009) 1.62
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
Epidemiology of post-infarction risk stratification strategies in a country with a low volume of revascularization procedures. GISSI-Prognosis Investigators. Eur Heart J (1998) 1.56
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost (1991) 1.55
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet (1992) 1.54
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia (2006) 1.51
Accuracy and reliability of frozen section diagnosis in a series of 672 nonpalpable breast lesions. Am J Clin Pathol (1995) 1.51
Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood (1998) 1.49
High prevalence of human T cell lymphotropic virus type II infection in patients affected by human immunodeficiency virus type 1--associated predominantly sensory polyneuropathy. J Infect Dis (1995) 1.47
Healthcare costs of multiple myeloma: an Italian study. Eur J Cancer Care (Engl) (2011) 1.47
Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol (1996) 1.45
Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev (1994) 1.42
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol (1990) 1.42
Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol (1993) 1.42
Thallium-201 reverse redistribution at reinjection imaging correlated with coronary lesion, wall motion abnormality and tissue viability. J Nucl Med (1996) 1.41
The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med (2007) 1.40
Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer (1992) 1.39
Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Lancet (1990) 1.38
Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol (1986) 1.37
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Terrestrial gamma-ray flashes as powerful particle accelerators. Phys Rev Lett (2011) 1.35
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia (2007) 1.35
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood (2000) 1.34
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther (2000) 1.34
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Use of the normalcy index for the evaluation of gait pathology. Gait Posture (2004) 1.28
High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood (1991) 1.25
Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation (2000) 1.24
Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) Ann Oncol (1999) 1.24
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 1.23
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol (2004) 1.22
Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry (1996) 1.19
Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol (2001) 1.18
Biomechanical analysis of sit-to-stand movement in normal and obese subjects. Clin Biomech (Bristol, Avon) (2003) 1.17
Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood (1999) 1.17
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother (2000) 1.17
Reproductive history and gastric cancer among post-menopausal women. Int J Cancer (1994) 1.16
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther (2000) 1.16
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia (2008) 1.15
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer (1990) 1.15
Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res (1995) 1.13
Discovery of powerful gamma-ray flares from the Crab Nebula. Science (2011) 1.13
Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica (1997) 1.12
Factor VIII-related properties in platelets from patients with von Willebrand's disease. J Lab Clin Med (1978) 1.12
Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther (1998) 1.10
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol (2006) 1.09
What are RBC-transfusion-dependence and -independence? Leuk Res (2010) 1.09
Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood (1989) 1.08
Subunits A and S inheritance in four families with congenital factor XIII deficiency. Br J Haematol (1978) 1.08
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol (2000) 1.07
T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. J Exp Med (1985) 1.07
A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). Scand J Gastroenterol (1996) 1.06
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med (2010) 1.05
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood (2001) 1.05
Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma. AIDS Res Hum Retroviruses (1996) 1.05
Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood (1997) 1.04
Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect (2000) 1.04
Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood (1997) 1.04
Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol (2001) 1.04
Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology (1991) 1.03
Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. J Clin Oncol (1989) 1.02
Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost (1997) 1.02
Functional dissection of the cis-acting sequences of the Arabidopsis transposable element Tag1 reveals dissimilar subterminal sequence and minimal spacing requirements for transposition. Genetics (2001) 1.02
Trends in mortality from leukemia in subsequent age groups. Leukemia (2000) 1.02
AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy. HIV Med (2009) 1.02
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia (2011) 1.00
Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol (1996) 1.00
Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. J Infect Dis (1997) 0.99
Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. Science (1997) 0.99
Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS (1996) 0.99